ArticlePloS one2014
Clinical and serological features of patients referred through a rheumatology triage system because of positive antinuclear antibodies.
Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed.
- Challenges in the diagnosis of systemic lupus erythematosus.Clinical medicine (London, England) · 2025Review
- Dense fine speckled antinuclear antibody patterns: Clinical correlations and implications.Current rheumatology research · 2025Article
- The Nuclear Dense Fine Speckled (DFS) Immunofluorescence Pattern: Not All Roads Lead to DFS70/LEDGFp75.Diagnostics (Basel, Switzerland) · 2023Article
- Clinical Significance of Different Profiles of anti-Ro Antibodies in Connective Tissue Diseases.Journal of immunology research · 2023Article
- Analysis of Ana/Dfs70 Pattern in a Large Cohort of Autoimmune/Autoinflammatory Diseases Compared with First Degree Relatives and Healthy Controls Evaluated from Colombia.Diagnostics (Basel, Switzerland) · 2022Article
- The influence of demography and referral medical specialty on the detection of autoantibodies to HEP-2 cells in a large sample of patients.Advances in rheumatology (London, England) · 2022Article
- Diagnostic Value of Anti-Nuclear Antibodies: Results From Korean University-Affiliated Hospitals.Journal of Korean medical science · 2022Article
- Random forests algorithm boosts genetic risk prediction of systemic lupus erythematosus.Frontiers in genetics · 2022Article
- Anti-DFS70 Antibodies Are Associated With Proliferative Lupus Nephritis and Renal Pathological Activity.Frontiers in immunology · 2022Article
- Low Prevalence of Anti-DFS70 Antibodies in Children With ANA-Associated Autoimmune Disease.Frontiers in pediatrics · 2022Article
- Comparison of the analytical and clinical performances of two different routine testing protocols for antinuclear antibody screening.Journal of clinical laboratory analysis · 2021Article
- Anti-DFS70 Antibodies for Differentiating Systemic Autoimmune Rheumatic Disease in Patients with Positive ANA Tests: A Systematic Review and Meta-Analysis.Diagnostics (Basel, Switzerland) · 2021Review
- Twenty years of research on the DFS70/LEDGF autoantibody-autoantigen system: many lessons learned but still many questions.Auto- immunity highlights · 2020Review
- Prediction of autoimmune connective tissue disease in an at-risk cohort: prognostic value of a novel two-score system for interferon status.Annals of the rheumatic diseases · 2018Observational
- Recognition and Relevance of Anti-DFS70 Autoantibodies in Routine Antinuclear Autoantibodies Testing at a Community Hospital.Frontiers in medicine · 2018Article
- The Clinical Relevance of Anti-DFS70 Autoantibodies.Clinical reviews in allergy & immunology · 2017Review
- The ANA-reflex test as a model for improving clinical appropriateness in autoimmune diagnostics.Auto- immunity highlights · 2016Article
- The significance of autoantibodies to DFS70/LEDGFp75 in health and disease: integrating basic science with clinical understanding.Clinical and experimental medicine · 2016Review
- [Antinuclear antibodies without connective tissue disease : Antibodies against LEDGF/DSF70].Zeitschrift fur Rheumatologie · 2016Review
- Confirmation of anti-DFS70 antibodies is needed in routine clinical samples with DFS staining pattern.Central-European journal of immunology · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe referral of patients with positive anti-nuclear antibody (ANA) tests has been criticized as an inappropriate use of medical resources. The utility of a positive ANA test in a central triage (CT) system was studied by determining the autoantibody profiles and clinical diagnoses of patients referred to rheumatologists through a CT system because of a positive ANA test.
methodsPatients that met three criteria were included: (1) referred to Rheumatology CT over a three year interval; (2) reason for referral was a "positive ANA"; (3) were evaluated by a certified rheumatologist. The CT clinical database was used to obtain demographic and clinical information and a serological database was used to retrieve specific ANA and/or extractable nuclear antigen (ENA) test results. Clinical information was extracted from the consulting rheumatologist's report.
results15,357 patients were referred through the CT system; 643 (4.1%) of these because of a positive ANA and of these 263 (40.9%) were evaluated by a certified rheumatologist. In 63/263 (24%) of ANA positive patients, the specialist provided a diagnosis of an ANA associated rheumatic disease (AARD) while 69 (26.2%) had no evidence of any disease; 102 (38.8%) had other rheumatologic diagnoses and 29 (11%) had conditions that did not meet AARD classification criteria. Of ANA positive archived sera, 15.1% were anti-DFS70 positive and 91.2% of these did not have an AARD.
conclusionsThis is the first study to evaluate the serological and clinical features of patients referred through a CT system because of a positive ANA. The spectrum of autoantibody specificities was wide with anti-Ro52/TRIM21 being the most common autoantibody detected. Approximately 15% of referrals had only antibodies to DFS70, the vast majority of which did not have clinical evidence for an AARD. These findings provide insight into the utility of autoantibody testing in a CT system.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.